tbuckley/cabot-search huggingface dataset:
ALLERGY
Authors: W. N. GOLDSMITH, M.R.C.P. LOND
Journal: British Journal of Dermatology (1936)

Journal Article ALLERGY Get access W. N. GOLDSMITH, M.D., W. N. GOLDSMITH, M.D. Search for other works by this author on: Oxford Academic Google Scholar M.R.C.P. LOND M.R.C.P. LOND Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 48, Issue 11, 1 November 1936, Pages 593–600, https://doi.org/10.1111/j.1365-2133.1936.tb10003.x Published: 01 November 1936
Commentaire de travail de A. Horiuchi et al., pp. 722
Journal: Endoscopy (2008)

See also: Prospective randomized trial comparing the direct method using a 24 Fr bumper-button-type device with the pull method for percutaneous endoscopic gastrostomyEndoscopy 2008; 40(09): 722-726DOI: 10.1055/s-2008-1077490
Normal infant born to a mother with phenylketonuria
Authors: M. S. Tenbrinck
Journal: JAMA (1982)

Following the introduction of artificial diets, a generation of women with phenylketonuria (PKU) has matured, and some of these women have reproduced. Offspring of these PKU mothers without PKU have multiple stigmata at birth, including mental retardation. To avoid harmful effects to the fetus, these mothers can be treated successfully by a low phenylalanine diet. This report of a case of the birth of a bright unaffected child includes specific diets for prepregnancy trial and maintenance during pregnancy. (<i>JAMA</i>1982;247:2139-2140)
Nuclear weapons testing fallout and thyroid disease
Authors: R. E. Lapp
Journal: JAMA (1994)

<h3>In Reply.</h3> —Dr Dworkin is correct in stating that our dosimetry method has not previously been applied in an epidemiological context. However, the methods used to determine the doses in our study are based on mathematical models of radionuclides that have evolved over many years. In particular, the transport of<sup>131</sup>I, the principal source of exposure to the thyroid, has been well established and validated. The unique aspect of our method is that it incorporates information that is based on the ability of individuals to recall residence history, diet, and lifestyle information 30 years after it occurred. The most important data reported for a specific time period consisted of three facts: (1) the individual's residence, (2) whether fresh milk was consumed, and (3) whether the milk came from a commercial dairy or a family cow. We strongly believe that the subjects' parents were able to provide this information accurately.
Small-vessel cutaneous vasculitis
Authors: G. E. Ehrlich
Journal: JAMA (1982)

The major aim of descriptive clinical studies should be to define identifiable subgroups and syndromes for their prognostic and therapeutic importance. Prognosis is coming into its own as a discipline<sup>1</sup>and remains the hidden question behind the patient's desire to know the diagnosis. Clinicians must incorporate it into their explanation or run the risk of being like the physician in Matthew Arnold's quatrain: Nor bring to watch me cease to live some doctor, full of phrase and fame to shake his sapient head and give the ill he cannot cure a name. To deliver a diagnosis without elaborating on what it means for the future is to send the patient to other sources for the information, many of which he cannot use properly. The diagnosis of vasculitis is one such potential trouble spot. A whole spectrum of conditions is included under that simple label, among which can be found
Nasogastric suction in the treatment of alcoholic pancreatitis. A controlled study
Authors: J. A. Levant
Journal: JAMA (1974)

Twenty-nine patients with mild to moderately severe acute alcoholic pancreatitis were randomly allocated to treatment with or without nasogastric suction. Antibiotics, anticholinergics, and antacids were not used. No significant differences were found between the two groups in duration of the following: abdominal pain, abdominal tenderness, nausea, narcotic requirement, fever, and elevated serum and urine amylase levels. The data suggested that even though a larger proportion of patients treated with suction became pain-free within the first two days of treatment, treatment without suction was associated with earlier return of normal bowel sounds and smaller risk of prolonged hyperamylasemia. Because nasogastric suction provided no clear-cut advantages in this admittedly small group, it might be considered elective rather than mandatory in the treatment of mild to moderately severe acute alcoholic pancreatitis. (<i>JAMA</i>229:51-52, 1974)
Transactions of the American Microscopical Society.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reducing junior doctors' hours.
Journal: BMJ (1991)

A second criticism is that treatment with intra- nasal steroid aerosols was deliberately withheld from all subjects.It is now generally accepted that this form of treatment is so effective for seasonal allergic rhinitis that if it is allowed immunotherapy cannot produce a significant improvement in symptom scores.Nevertheless, for severe hay fever steroid aerosols are the standard treatment with which immunotherapy must be compared (together with its risks).To give suboptimal supportive treatment to patients treated with placebo might be acceptable in a trial of some exceedingly important new form of treatment, provided the position was made clear to the volunteers.In a trial of yet another formulation of conventional vaccine for hay fever the ethics seem dubious.The third point of criticism concerns the discussion of the reactions experienced by patients in the trial.Although 523 active injections were administered, there were only 21 actively treated patients.The necessary courses of injection that they received provoked an episode of anaphylaxis in one and generalised urticaria in another: a reaction rate of nearly 10%.The instances of fatal
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)
Authors: V. Hirsh, M. Boyer, R. Rosell, R. J. Benner, D. Readett, J. H. Schiller
Journal: Journal of Clinical Oncology (2008)

8016 Background: Paclitaxel/carboplatin (PC) is standard first line therapy for patients (pts) with Stage IIIB/IV NSCLC. PF- 3512676 (PF-676) is an oligodeoxynucleotide toll-like receptor 9 (TLR9) agonist. In a randomized phase 2 trial, addition of PF-676 to first line taxane/platinum chemotherapy produced a higher objective response rate and a trend toward improved overall survival (OS) in pts with advanced NSCLC. Confirmatory phase 3 trials were subsequently conducted. Methods: Chemotherapy naive pts with Stage IIIB (pleural effusion) or Stage IV NSCLC, ECOG PS 0 or 1, measurable disease, adequate bone marrow, renal and hepatic function, no pre-existing autoimmune disease, no brain metastases and no chronic systemic corticosteroid therapy were included. All pts received P (200 mg/m2) and C (AUC 6) IV on D1 of each 21 day cycle (max 6 cycles). In the investigational arm pts also received PF-676 (0.2 mg/kg) SC on D 8 and 15 of each chemotherapy cycle and weekly thereafter until progression. The primary endpoint was OS. Results: 828 pts were randomized (409 PC + PF-676, 419 PC) from Dec ‘05 to April ‘07. Interim data reviewed by an external DSMC is reported. No increment in OS (98 deaths on PC + PF-676, 99 on PC [HR 0.971 95 % CI 0.76, 1.26]) or PFS (Median 4.6 mos on PC+PF-676, 4.4 mos on PC) was noted for the addition of PF-676. Many pts in the PF-676 arm experienced mild/moderate injection site reactions (65% [4 % G3/4]) or flu-like symptoms (50% [3 % G3/4]). G3/4/5 neutropenia and thrombocytopenia and septic episodes were reported more commonly in pts receiving PF-676 (63% vs 52%; 14% vs 6%; 4% vs 0.5%). The DSMC recommended termination of the trial due to lack of incremental efficacy and added toxicity. PF-676 administration was discontinued in all pts but collection of follow-up data continues. Updated results will be reported. Conclusions: Addition of PF-676 to PC did not improve the outcome of pts with advanced NSCLC. Alternative development opportunities are being explored for TLR-9 agonists in the treatment of cancer. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pfizer Pfizer Oncology Pfizer Pfizer Oncology
The Rational Clinical Examination
Authors: Neal Devitt
Journal: JAMA (1992)

<h3>To the Editor.</h3> —I was pleased to read your introduction to the new series on clinical examination. I thought the initial article<sup>1</sup>and Editorial<sup>2</sup>were both excellent. I would like to present the following case to pose a question: Four weeks ago, an 82-year-old woman came into my office with a 1-month history of right leg swelling. During this month, she had three separate episodes of pleuritic chest pain, the first two of which resolved spontaneously. She came to the office after the third episode of pain. On examination, she was found to have râles medial to her left scapula without audible rub. Her right leg was swollen and tender with a circumference of 40 cm compared with a left leg circumference of 35 cm. I felt absolutely certain that she had a deep-vein thrombosis with recurrent pulmonary emboli. I admitted her to the hospital where a venous
PWE-088 Risk of developing dysplasia/cancer in patients with short segment Barrett's oesophagus is similar to long segment Barrett's oesophagus
Authors: V Subramanian, N Palaniyappan, A Lee, J Mannath, C J Hawkey, K Ragunath
Journal: Gut (2010)

<h3>Introduction</h3> There is increasing evidence that the incidence of Barrett9s oesophagus (BO) is increasing and the majority of these are the short segment (SSBO) variety. At the same time the incidence of oesophageal adenocarcinoma is also on the rise. While it is generally accepted that long segment Barrett9s oesophagus (LSBO) is associated with an increased risk of developing dysplasia/cancer, the risk associated with SSBO is poorly defined. <h3>Aim</h3> To estimate the risk of developing high-grade dysplasia/cancer in patients with SSBE and LSBE undergoing surveillance endoscopy. <h3>Methods</h3> We identified patients, from the endoscopic records of Nottingham University Hospital, with a confirmed endoscopic and histological diagnosis of BO from 2002 to 2006. Duration of follow-up was calculated from the time the first histological diagnosis of BO was made to the time of the last endoscopy. Incidence density (ID) of developing high-grade dysplasia/cancer and incidence rate ratios (IRR) were calculated in patients with SSBE and LSBE. A Poisson distribution was assumed for purposes of calculation and analysis for IRR was adjusted for age and sex. Data were analysed using Stata V.9.1. <h3>Results</h3> 703 patients with a confirmed histological diagnosis of BO were identified from the database. 470 patients (339 male and 139 female) had LSBO and 233 patients (141 male and 92 female) had SSBO. There were 70 dysplastic lesions (54 HGD/cancer and 26 LGD) in patients with LSBO and 16 dysplastic lesions (10 HGD/cancer and six LGD) in patients with SSBO. The crude incidence density of developing HGD/cancer in patients with LSBO was 31.5/1000 pyd (person years duration) (95% CI 23.7 to 41.2) and in patients with SSBO was 15.1/1000 pyd (95% CI 7.3 to 27.8). The age and sex adjusted incidence rate ratio of developing HGD/cancer among patients with SSBO compared to LSBO was 0.99 (95% CI 0.93 to 1.06). <h3>Conclusion</h3> The risk of developing HGD/cancer in patients with SSBO appear to be similar to those with LSBO. Surveillance guidelines and physicians need to take this into account when planning surveillance strategies for patients with SSBO.
Long-term outcome after argon plasma coagulation of small-bowel lesions using double-balloon enteroscopy in patients with mid-gastrointestinal bleeding
Authors: A. May, T. Friesing-Sosnik, H Manner, J. Pohl, C. Ell
Journal: Endoscopy (2012)

Correction to: Long-term outcome after argon plasma coagulation of small-bowel lesions using double-balloon enteroscopy in patients with mid-gastrointestinal bleedingEndoscopy 2011; 43(09): 759-765DOI: 10.1055/s-0030-1256388
Preclinical Safety of Baxter's Recombinant Factor IX
Authors: Barbara Dietrich, Susan Kubik, Wilfried Auer, Kuno Wuersch, Birgit Reipert, Frank Horling, Martin Wolfsegger, Hartmut J. Ehrlich, Friedrich Scheiflinger, Hans Peter Schwarz, Eva-Maria Muchitsch
Journal: Blood (2010)
Epithelioid haemangioendothelioma.
Authors: Nadia Yousaf, Charlotte Benson, Omar Al-muderis, Cyril Fisher, Ian Robert Judson
Journal: Journal of Clinical Oncology (2013)

10569 Background: Epithelioid haemangioendothelioma (EHE) is a rare vascular tumour which can arise in any site. There is little published data about the clinical behaviour and management of these tumours. Methods: A retrospective review of the management of patients with histologically proven EHE presenting to the Royal Marsden Hospital from January 1999 to January 2012. Demographics, site, treatment and survival outcomes were collected. Results: 28 patients (21 females) were identified with a mean (SD) age of 44 (17). 20 patients presented with diffuse disease involving one or more organs at presentation. The predominant site of disease was identified as liver n=8, mediastinum n=6, lung n= 2, limb n=1, pancreas n=1, spleen n=1, back n=1, abdominal wall n=1, oesophagus n=1, neck n=1, pelvis n=1, not known n=2. Median overall survival (Interquartile range) [OS (IQR)] in months was the longest in 10 patients who had localised operable disease at presentation, 116 (71). Amongst those with inoperable disease (n=16), patients with liver disease had the longest OS (IQR), 18 (43) months and those with lung and mediastinal disease had the shortest OS (IQR), 10 (2.5) and 11 (17) months respectively. A variety of treatment modalities were used for patients with inoperable disease and these are summarised in the Table. Conclusions: The clinical behaviour of EHE can vary depending on the site of disease. Surgery, if feasible, has the best outcome. In those with inoperable disease a period of observation to assess the clinical behaviour of the tumour is recommended. Non-steroidal anti-inflammatory drugs are a reasonable, relatively non-toxic first line treatment option. The use of anti-angiogenic drugs merits further exploration. [Table: see text]
Useful Noise
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 659: Integrated therapeutic antibody development at the National Research Council of Canada
Authors: Maria L. Jaramillo, Anne Marcil, Yves Durocher, Renald Gilbert, Alaka Mullick, John Kelly, Maureen O'Connor-McCourt, Bernard Massie
Journal: Cancer Research (2014)

Abstract Advances in genomics and antibody engineering have enabled the development of an innovative class of targeted therapies, namely therapeutic antibodies, for the treatment of diseases with significant unmet medical needs such as cancer. Therapeutic antibodies represent one of the largest and fastest growing classes of medications. The National Research Council of Canada (NRC) has built a chain of cutting edge technology platforms needed to discover, engineer and produce therapeutic monoclonal antibodies with the goal of partnering with industrial and academic centers to advance research and development of this important class of therapeutics. Target Identification- Tumor targets were identified using a combination of proteomics, transcriptomics and bioinformatic approaches. Out of these lists, approximately 40 tumor targets were selected and over 3,000 antibodies of mouse and camelid origin were generated against these targets. Antibody generation can be done conventionally, using the recombinant target protein produced using NRC's high efficiency cell expression platforms in CHO or HEK293 cells or by direct immunization with plasmid DNA constructs. Clone selection is carried out by ELISA and typically 50 antibodies/target are identified for further characterization. Antibody characterization and validation- The affinities of the antibodies are determined by SPR biosensor analysis. Epitope mapping can be carried out so that representative antibodies can be selected for further validation in appropriate cell-based assays (many of which are established at NRC) and animal models. Therapeutic antibody Optimization, Bioprocessing and Biomanufacturing- Therapeutic antibodies selected for development can be further optimized using antibody engineering technologies to humanize them and/or modify their glycosylation patterns to improve their effector function, pharmacokinetics, solubility and stability as well as reduce their immunogenicity. The NRC platform for large scale protein production has the capacity to manufacture up to 500 g of commercial grade antibody in a cGMP certified CHO cell line which is ready for transfer to CMOs . Citation Format: Maria L. Jaramillo, Anne Marcil, Yves Durocher, Renald Gilbert, Alaka Mullick, John Kelly, Maureen O'Connor-McCourt, Bernard Massie. Integrated therapeutic antibody development at the National Research Council of Canada. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 659. doi:10.1158/1538-7445.AM2014-659
Substance of some Remarks concerning Cases of Valvular Disease of the Heart, known to have Existed for over Five Years without Causing Serious Symptoms
Authors: A. Clark
Journal: BMJ (1887)

much of him, can tell so fully of what he was; can so perpetuate him in the vast store of facts, in the purpose for which they are set forth, in the illustration of principles, in the suggestion of truths beyond those it can show, above those it can reAch; in all this, I say, no memorial, however majestic, can rival our Aluseum.The foundation of this with his own hand and his whole heart he laid; it has grown and still is growing from his strength, and it must be made for ever worthy of his namo.
INDIA
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Addendum: Volunteer Opportunities Overseas
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal